Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Guardian Pharmacy Services (GRDN) Cash & Equivalents (2023 - 2025)

Guardian Pharmacy Services (GRDN) has disclosed Cash & Equivalents for 3 consecutive years, with $65.6 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents rose 1308.13% to $65.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $65.6 million through Dec 2025, up 1308.13% year-over-year, with the annual reading at $65.6 million for FY2025, 1308.13% up from the prior year.
  • Cash & Equivalents hit $65.6 million in Q4 2025 for Guardian Pharmacy Services, up from $36.5 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $65.6 million in Q4 2025 to a low of $752000.0 in Q4 2023.
  • Historically, Cash & Equivalents has averaged $25.4 million across 3 years, with a median of $18.8 million in 2025.
  • Biggest YoY gain for Cash & Equivalents was 1308.13% in 2025; the steepest drop was 1.97% in 2025.
  • Year by year, Cash & Equivalents stood at $752000.0 in 2023, then surged by 519.68% to $4.7 million in 2024, then soared by 1308.13% to $65.6 million in 2025.
  • Business Quant data shows Cash & Equivalents for GRDN at $65.6 million in Q4 2025, $36.5 million in Q3 2025, and $18.8 million in Q2 2025.